Even though they probably already pulled in payment for the approved shipment, they have already said that they are deferring revenue until the FDA approves the drug. So I don't see how they will have positive earnings yet.
That statement they made does not seem right. I am not an accountant, but what happens if Arestvyr never gets FDA approval? That means SIGA will never have to report revenues from the $433M contract. I am sure IRS is going to want their share.
It is my assumption the analysts are using a non-GAAP projection for this reason. EBITDA Or Cash EPS or some other form of analyzing. Their projected Earnings for next year do seem to reflect sharing profits with PIP, which may or may not be the case.